title: [Clinical aspect of recent progress in phosphate metabolism. Treatment of hypophophatemia].
abstract: Most hypophosphatemic patients will not require immediate replacement therapy with phosphate. In only the patients with acute severe hypophosphatemia (<1 mg/dL) or symptoms, intravenous phosphate replacement therapy is indicated. On the other hand, the patients with chronic hypophosphatemia require the medical treatment with oral administration of calcitriol and neutral phosphate since this condition causes hypophosphatemic rickets/osteomalacia. However, the treatment regimen has not been standardized, and nephrocalcinosis and tertially hyperparathyroidism are the complication of the long-term treatment. Adjuvant therapy with calcimimetics or suppression therapy for FGF23 action may improve long-term outcome.
authors.affiliation: Department of Pediatrics, Graduate School of Medicine, Chiba University.
authors.forename: Masanori
authors.initials: M
authors.lastname: Minagawa
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D002117:Calcitriol / Q000008:administration & dosage; D002908:Chronic Disease; D015195:Drug Design; D053098:Familial Hypophosphatemic Rickets / Q000209:etiology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors; D006801:Humans; D017674:Hypophosphatemia / Q000209:etiology / Q000628:therapy*; D007262:Infusions, Intravenous; D010018:Osteomalacia / Q000209:etiology; D010710:Phosphates / Q000008:administration & dosage*; D044169:Receptors, Calcium-Sensing / Q000819:agonists
chemical_list: C000717427:FGF23 protein, human; D010710:Phosphates; D044169:Receptors, Calcium-Sensing; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D002117:Calcitriol